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Abstract
Caveolin-1 (Cav1), a structural protein required for the formation of invaginated membrane domains known as caveolae, has
been implicated in cholesterol trafficking and homeostasis. Here we investigated the contribution of Cav1 to apolipoprotein
A-I (apoA-I) cell surface binding and intracellular processing using mouse embryonic fibroblasts (MEFs) derived from wild
type (WT) or Cav1-deficient (Cav12/2) animals. We found that cells expressing Cav1 have 2.6-fold more apoA-I binding sites
than Cav12/2 cells although these additional binding sites are not associated with detergent-free lipid rafts. Further, Cav1-
mediated binding targets apoA-I for internalization and degradation and these processes are not correlated to cholesterol
efflux. Despite lower apoA-I binding, cholesterol efflux from Cav12/2 MEFs is 1.7-fold higher than from WT MEFs.
Stimulation of ABCA1 expression with an LXR agonist enhances cholesterol efflux from both WT and Cav12/2 cells without
increasing apoA-I surface binding or affecting apoA-I processing. Our results indicate that there are at least two
independent lipid binding sites for apoA-I; Cav1-mediated apoA-I surface binding and uptake is not linked to cholesterol
efflux, indicating that membrane domains other than caveolae regulate ABCA1-mediated cholesterol efflux.
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Introduction
Expression of caveolin-1 (Cav1) and cavin proteins in
mammalian cells drives the formation of small (50–100 nm)
invaginations of the plasma membrane known as caveolae [1,2,3].
Caveolae are regarded as a subtype of a group of specialized
membrane microdomains, i.e. lipid rafts [4] that are characterized
by their enrichment in cholesterol and sphingolipids [5,6]. Both
the expression of Cav1 and the formation of caveolae are
dependent on cellular cholesterol levels [7]. Cav1 mutations in
patients are linked to lipid disorders [8] and Cav1 itself is a high-
affinity cholesterol binding protein [9]. Cav1 has been implicated
in controlling the intracellular balance between free and esterified
cholesterol [10] and interacting with many lipid transporters [11].
Studies in which Cav1 expression is increased or knocked out
indicate that Cav1 regulates storage of lipids in cytoplasmic lipid
droplets in adipocytes and hepatocytes [12,13,14]. It has also been
suggested that Cav1 promotes the transport of newly synthesized
cholesterol from the endoplasmic reticulum to outer leaflet of the
plasma membrane, where it is accessible to extracellular
cholesterol oxidase [15,16].
Cholesterol export from the plasma membrane to extracellular
acceptors is the first step in the ‘reverse cholesterol transport’
pathway, which delivers excess cholesterol from peripheral tissues
back to the liver. Cholesterol efflux is tightly controlled, and the
pathways involved depend on the nature of the extracellular
acceptor [17]. Cholesterol efflux to apolipoprotein A-I (apoA-I),
the major protein component of high-density lipoproteins (HDL),
utilizes the ATP-binding cassette transporter A1 (ABCA1), which
is probably not associated with lipid rafts [18] but may alter
cholesterol distribution within the plasma membrane [19,20,
21,22]. Efflux to HDL is mediated by other transporters such as
scavenger receptor class B type I (SR-BI) and ABCG1
[20,23,24,25]. Treatments that disrupt lipid raft structure have
little effect on HDL-dependent cholesterol export [26] but raft
integrity may be required for HDL-induced cholesterol ester
exchange [27].
There are inconsistent reports regarding the role of Cav1 in
cholesterol export. Fu et al. transiently increased Cav1 in hepatic
cells and found enhanced cholesterol export to apoA-I and HDL-
containing plasma [28] (later confirmed in [29]), which is
consistent with the previous finding that apoA-I induces
cholesterol trafficking to caveolae [30]. Reducing expression of
Cav1 in human monocyte-derived macrophages also reduced
cholesterol efflux to apoA-I and HDL [31]. In contrast, down-
regulation of Cav1 in NIH3T3 fibroblast increased cholesterol
efflux to HDL [32] contradicting earlier results in human skin
fibroblasts [33]. Over-expression of Cav1 in mouse macrophage
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cell lines had no effect on HDL-mediated efflux [34]. In
embryonic fibroblasts and peritoneal macrophages from Cav1-
deficient mice (Cav12/2), cholesterol export to HDL was not
different to that from the wild-type (WT) cells [10]. Those
differences may be attributed to differential effects in different cell
types and the effect Cav1 expression has on other cholesterol
transporters. For example, Cav1 expression inhibits SR-BI-
mediated cholesterol influx [34] although this was not the case
in HEK-293T cells [35]; increases cholesterol uptake in macro-
phages [36] and hepatic cells [29]; and had no effect uptake and
export in Fischer rat thyroid cells and HEK 293 cells [37]. The
effect of Cav1 expression on ABC transporter has been reported
for endothelial cells, in which Cav1 expression correlates with
ABCA1 expression and thus modulates cholesterol efflux [38,39].
To add to the complications, there is an ongoing debate
whether apoA-I internalization and recycling is required for apoA-
I-mediated efflux or whether apoA-I interactions with lipid
domains on the cell surface are sufficient. An earlier report found
that a substantial proportion of apoA-I was endocytosed and re-
secreted from mouse macrophages [40]. This has been recently
confirmed suggesting that in mouse macrophages ABCA1-
mediated apoA-I, but not HDL uptake is required for cholesterol
efflux [41]. Similarly, Hassan et al. suggest that apoA-I re-
secretion is mainly responsible for cholesterol export from BHK
cells that stably express ABCA1 [42]. In contrast, two recent
papers found that apoA-I retroendocytosis is not sufficient for
cholesterol efflux from mouse macrophages [43] and ABCA1-
expressing BHK cells [44].
Given this controversy and that earlier papers studied
cholesterol efflux independently from apoA-I binding and
processing, we re-investigated how Cav1 expression affects
apoA-I binding to the plasma membrane, apoA-I internalization
and cholesterol efflux. We used wild-type (WT) and Cav12/2
mouse embryonic fibroblasts (MEFs) because the genetic deletion
of Cav1 ensures that Cav12/2 MEFs have no detectable caveolae
[45] but comparable levels of SR-BI, ABCA1 and ABCG1, as
found here. We induced the expression of ABCA1 in these cells
with a potent LXR agonist, T0901317. We found a higher
number of apoA-I binding sites on WT cells than Cav12/2MEFs,
which correlated with enhanced apoA-I internalization and
degradation. However, Cav1-mediated internalization was not
required for cholesterol efflux in this cell type. In summary, our
results indicate that surface binding outside caveolae is sufficient to
regulate ABCA1-mediated cholesterol efflux from fibroblast
suggesting that membrane domains other than caveolae have an
important role in cholesterol export.
Materials and Methods
Cells and Reagents
Mouse embryonic fibroblasts (MEFs) were prepared from 13.5
p.c. embryos obtained by homozygous crossings of Cav12/2 mice
or WT mice (approved by the Regional Ethics Committee for
Animal experiment, Nu3 of Ile de France, Paris; Approval ID : p3/
2008/013) [45]. MEF cells were immortalized by continuous
passages until growth rates in culture resumed the rapid rates seen
in early passages. MEFs were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (v/v) FCS,
2 mM L-glutamine, 100 units/L penicillin, and 100 mg/L
streptomycin at 37uC in 5% CO2. Where indicated, cells were
treated with the LXR ligand T0901317 (1 mM) for 18 h. Bovine
serum albumin (BSA, essentially fatty acid free), Dulbecco’s
phosphate buffered saline (PBS), chloramphenicol, cholesterol
and cholestenone were purchased from Sigma. [3H]-cholesterol
(48.0 Ci/mmol) and [125I]-iodine were obtained from Amersham.
ApoA-I was delipidated and purified as described previously [46].
ApoA-I binding measurements
ApoA-I labeling. Iodine incorporation into apoA-I was
carried out as described previously [47]. Briefly, 125Iodine
(10 mCi; Amersham) was incubated with one IODO bead
(Pierce) for 2 min before apoA-I (1–3 mg) was added. After
1 min, free iodine was separated from [125I]-apoA-I by gel
filtration (PD10; Pharmacia). Typically, a specific activity of
500 dpm/ng apoA-I was achieved with ,3% free iodine
contamination.
ApoA-I binding at 46C. For binding experiments, cells were
place on ice and incubated with [125I]-apoA-I (0–75 mg/mL) in
DMEM for 90 min at 4uC. Non-specific binding, typically ,20%
of specific binding independent of cell type, was measured in the
presence of a 10-fold excess of unlabelled apoA-I [47]. Specific
binding was calculated from the difference between total and non-
specific binding. At the end of the incubation, cells were washed
twice to remove unbound apoA-I and cells were lysed in 0.2 M
NaOH and counted for [125I] radioactivity.
Binding coefficients. To obtain values for maximal apoA-I
binding (Bmax, ng/mg) and the apoA-I concentration at which half
of the maximum binding was achieved (KD, mg/mL), apoA-I
calibration curves were fitted to
½ApoA-1bound~Bmax|
½ApoA-1free
KDz½ApoA-1free
using a non-linear fitting algorithm (Microsoft Excel).
ApoA-I binding to membrane domains. To determine
apoA-I binding to membrane domains, cells were first incubated
with [125I]-apoA-I at 4uC and then washed and fractionated by
sonication and placed on a 5–45% sucrose gradient as described
below. Fractions were analyzed for [125I]-apoA-I. For controls,
cells pre-labeled with [3H]-cholesterol without [125I]-apoA-I and
[125I]-apoA-I without cells were fractionated. 95% of unbound
apoA-I was found in the heaviest fraction of the non-detergent raft
gradient und these controls were used to calculate the percentage
of bound apoA-I in each fraction as previously described [47].
Non-detergent raft isolation. Whole cell homogenates
(total volume 1.2 mL) were sonicated for 4630 s with a 3 mm
titanium probe (frequency 23 kHz, amplitude 30 microns) and
cooled on ice between bursts [48]. Samples were then adjusted to a
final concentration of 45% (w/v) sucrose by mixing with an equal
volume of 90% (w/v) sucrose in MBS (25 mM MES pH 6.5,
150 mM NaCl). 2.0 mL of the mixture was overlaid with 2.5 mL
of 35% (w/v) sucrose, 2.5 mL of 30% (w/v) sucrose, 2.5 mL of
25% (w/v) sucrose and 2.5 mL of 5% (w/v) sucrose (all in MBS)
[48]. The sucrose gradient was spun at 40,000 RPM in a Beckman
SW41 rotor (200,000 g) for 16 h. Twelve fractions of 1.0 mL were
collected from the top.
ApoA-I binding and processing at 376C. WT and Cav12/2
MEFs were incubated with 25 mg/mL 125I-apoA-I 610-fold
unlabeled apoA-I at 37uC for 15 min, 30 min, 1 h or 2 h. Specific
apoA-I binding was calculated as described above. Non-specific
binding in the presence of 10-fold excess of unlabeled apoA-I was
similar in WT and Cav12/2 MEFs and comparable to binding
experiments at 4uC. At the indicated times, the media were collected,
detached cells removed and degraded apoA-I in the media
determined as TCA-soluble 125I. Briefly, 0.25 mL media was mixed
with 0.5 mL of ice-cold 50% TCA (Sigma) and 125 mL of 0.7 M
AgNO3 (Sigma). The mixture was spun at 200 g for 15 min and the
supernatant collected and counted for degraded 125I-apoA-I. After the
Caveolin-1 and Apolipoprotein A-I
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media was removed, cells were washed twice with ice-cold PBS and
incubated with 0.5 mg/mL trypsin (Sigma) for 30 min at 4uC on ice.
Supernatants were collected, detached cells removed and 125I-apoA-I
counted to determine trypsin-sensitive e.g. surface-bound apoA-I. The
remaining cells were lysed, protein levels determined and trypsin-
resistant 125I-apoA-I counted to quantify internalized apoA-I. At each
time point and in each of the three compartments (surface-bound,
internalized and degraded apoA-I), non-specific apoA-I was similar in
both cell types and was subtracted to determine specific surface-
bound, internalized and degraded 125I-apoA-I. It should be noted that
the trypsin treatment that defined surface-bound apoA-I is only
8963% efficient (as quantified by apoA-I binding at 4uC) so that the
internalized (trypsin-resistant) apoA-I pool is slightly overestimated.
Immunoblotting
Cell lysates and plasma membranes isolated by subcellular
fractionation were prepared as previously described [47]. Equal
amounts of protein were run on 12.5% SDS/PAGE gels, blotted
and probed with various antibodies described in the figure legends.
Primary antibody detections were performed using appropriate
peroxidase-conjugated secondary IgGs and visualized using
enhanced chemiluminescence by exposure to Kodak autoradio-
graphic film. The polyclonal caveolin-1 antibody was from Santa
Cruz biotechnology. ABCA1 and SR-BI antibodies were from
Novus.
Sterol analysis
Cell lysates, plasma membrane and NDR were extracted as
described previously [46] and cholesterol and cholesterol esters
were analysed by reverse-phase HPLC.
Cholesterol and phospholipid efflux
To measure cholesterol efflux, cells were incubated for 24 h
with [1a,2a(n)-3H]cholesterol with and without LXR ligand
T0901317 (1 mM). To measure phospholipid efflux, cells were
labeled with [methyl-3H] choline chloride (Amersham). The cells
were washed twice with PBS followed by 90 min equilibration in
serum-free DMEM containing 1 mg/ml BSA (fatty acid-free).
Cholesterol efflux was measured in DMEM containing 1 mg/mL
BSA and with or without 10 mg/mL apoA-I or HDL2 by
determining [3H]-cholesterol in aliquots (100 mL) of media taken
at intervals [49,50]. Phospholipid efflux was determined after a
24 h efflux. At the end of the experiments cells were washed twice
in ice-cold PBS and lysed in 1 mL NaOH (0.2 M, Sigma).
Residual radioactivity was determined in the cell lysate. Efflux is
expressed as a percentage of the total counts in the system.
Results
Characterization of WT and Cav12/2 MEFs
We started our investigations with a characterization of WT and
Cav12/2 MEFs. Cav1 expression is essential for the formation of
caveolae, and cells from Cav12/2 mice show a complete lack of
morphologically identifiable caveolae [2,45]. Cav12/2 MEFs
contained no detectable levels of Cav1 while Cav2 levels in
Cav12/2 MEFs were severely reduced (12.8610.6%) compared
to WT MEFs [51].
ApoA-I mediated-cholesterol export critically depends on the
expression of ABCA1, a transporter that associates with non-raft
domains [47]. Under basal conditions, WT and Cav12/2 MEFs
expressed comparable levels of ABCA1 protein (Fig. 1A and B) and
mRNA (data not shown). To increase ABCA1 expression, we
treated cells with the specific LXR agonist T0901317. ABCA1
protein expression was increased ,4-fold in both cell types by the
LXR agonist and was slightly (,1.2-fold) higher in Cav12/2 than
WT MEFs (Fig. 1B). In contrast, SR-BI protein (Fig. 1A) and
mRNA levels (not shown) were similar between the two cell types
and were not affected by treatment with the LXR agonist. ABCG1
levels were also not significantly different, as judged by RT-PCR
(data not shown). We also assessed ABCA1 expression in the plasma
membrane (Fig. 1C). In response to LXR agonist treatment, both
cell types increased ABCA1 surface expression ,2-fold. However,
despite higher cellular ABCA1 levels, Cav12/2 MEFs had
respectively 1.8-fold and 2.4-fold less ABCA1 at the cell surface
than WT MEFs in the absence and presence of the LXR agonist
(Fig. 1D).
Because caveolae are regarded as a subtype of lipid rafts [4] and
are enriched in cholesterol, we examined whether lipid raft
abundance is different in these two cell types. Lipid rafts including
caveolae can be isolated based as detergent-resistant membranes
(DRMs) or as a light membrane sub-fraction obtained after
mechanical disruption of cell membranes [48]. In all cell types
tested, Cav1 is predominantly associated with DRMs or light
membrane fractions of membranes [52]. Here, we compared the
cholesterol content of non-detergent raft domains (NDR) between
WT and Cav12/2 MEFs (Fig. 1E) that were prepared from cell
homogenates by sonication followed by separation on a 5–45%
sucrose density gradient. We previously reported that membrane-
associated cholesterol levels are similar in WT and Cav12/2
MEFs [51] and that ABCA1 is exclusively found in non-raft
factions on this gradient [47]. Lipid raft-favoring proteins Cav1
and flotillin-1 partitioned predominantly into fractions 2–5, while
the non-raft protein transferrin receptor was exclusively found in
fractions 8–12 (data not shown) [48]. WT MEFs contained
43.362.0% (or 21.262.1 nmol/mg cell protein) of cholesterol in
NDR compared to 35.465.3% (21.362.2 nmol/mg) in Cav12/2
MEFs (mean 6 s.d. of 3 separate experiments). Although the
proportion of cholesterol in NDR was consistently lower in
Cav12/2 MEFs, the difference in proportional distribution
between WT and Cav12/2 NDR cholesterol was not statistically
significant (P.0.05). A previous study indicated that the
distribution of proteins normally associated with lipid rafts is
unaffected by changes in Cav1 expression [53]. Together with the
data presented here, it can be speculated that either total lipid raft
domains (caveolae+non-caveolae rafts) are not dependent on Cav1
expression, or that caveolae represent only a small proportion of
total raft cholesterol.
ApoA-I binding to WT and Cav12/2 MEFs
Caveolae are the preferred binding sites of raftophilic toxins and
apoA-I binds directly to protein-free lipid bilayers. Thus it is
possible that caveolae are specific apoA-I binding sites. Therefore
we compared apoA-I surface binding to Cav12/2 MEFs with
binding to WT cells.
To measure binding, 125I-labelled apoA-I was bound to cells at
4uC. Non-specific binding was determined in the presence of 10-
fold excess of unlabelled apoA-I (similar in both cell types, data not
shown) and subtracted from total bound apoA-I to determine
specific apoA-I binding (Fig. 2). Specific binding was fitted to
Langmuir equation (Fig. 2A and B) to obtain the binding affinity
(KD) and number of binding sites (Bmax). While the binding affinity
for apoA-I was similar for both WT and Cav12/2MEFs, WT cells
displayed ,2.6-fold more apoA-I binding sites compared to
Cav12/2 MEFs (Fig. 2C).
Increasing ABCA1 expression levels by pretreatment with an
LXR agonist had no effect on apoA-I binding affinity (KD) and
number of binding sites (Bmax) in either cell type (Fig. 2B and C).
Even when ABCA1 surface expression is taken into account
Caveolin-1 and Apolipoprotein A-I
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(Fig. 1D), our data indicates that Cav1 expression, but not ABCA1
expression, increases apoA-I surface binding sites in MEFs:
Cav12/2MEFs treated with the LXR agonist had similar ABCA1
expression in the plasma membrane than untreated WT MEFs,
yet their apoA-I binding capacity is vastly different. In previous
reports, increased expression of ABCA1, either by stimulation or
ectopic expression increased apoA-I bindings sites in the mouse
macrophage line J774 [54] and BHK cells [42,55]. It is
noteworthy that neither of these cell types expresses detectable
levels of caveolin or caveolae [56,57] so that it is possible that
apoA-I binding in the complete absence of both ABCA1 and
Cav1, which is the basal condition in these studies, is non-specific.
This is not the case in Cav12/2 MEFs, which not only express
ABCA1 (Fig. 1A–D) but to which apoA-I binds with a similar high
affinity than to WT MEFs (kD in Fig. 2C).
Vedhachalam et al suggest that ABCA1-expressing cells have
two types of high affinity binding sites: apoA-I/ABCA1
interaction that account for only ,10% of bound apoA-I have
a low capacity (low Bmax) while apoA-I/lipid domain interactions
constitute high capacity binding sites [54]. It is thus possible that
caveolae in WT MEFs are high-affinity, high capacity apoA-I
binding sites, while the high-affinity, low capacity binding sites on
Cav12/2 MEFs are ABCA1-mediated. A 2-fold increase in
ABCA1 surface expression under LXR agonist treatment did
increase Bmax by 18% and 9% in WT and Cav1
2/2 MEFs,
respectively, but this increase was not significant in either cell
type given that the standard error for Bmax was .10%. Hence,
the low capacity of ABCA1-mediated apoA-I binding site may
explain why a 2-fold increase in ABCA1 surface expression did
not significantly increase total apoA-I binding.
Figure 1. Characterization of WT and Cav12/2MEFs. A. Protein expression of ABCA1 and SR-BI of WT and Cav12/2 MEF with and without LXR
agonist T0901317 treatment. B. Quantification of ABCA1 protein expression of Cav12/2 MEFs (hollow bars) relative to WT MEFs (filled bars) without
and with LXR agonist T0901317 treatment. C. ABCA1 expression in the plasma membrane with and without LXR agonist T0901317 treatment. D.
Relative ABCA1 cell surface expression in WT MEFs (filled bars) and Cav12/2 MEFs (hollow bars) without and with LXR agonist T0901317 treatment. E.
Cholesterol content in NDR and non-raft membranes in WT and Cav12/2 MEFs. Light and heavy membranes were prepared from whole cell
homogenate by sonication and separation on a 5–45% sucrose gradient as described in Methods. Twelve fractions are collected from the top of the
gradient. The distribution of cholesterol across the gradient was determined by fractionating WT (closed diamond) and Cav12/2 MEFs (open squares)
with incorporated 3H-cholesterol. The data show average 6 standard deviation of three independent experiments.
doi:10.1371/journal.pone.0023353.g001
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ApoA-I binding to Cav1-enriched membrane domains
We have previously shown that apoA-I binds predominantly to
non-raft domains on the plasma membrane of macrophages,
although a small, but significant proportion of apoA-I binds to
cholesterol-rich non-detergent rafts (NDR). Furthermore, we
demonstrated that apoA-I binding to the NDR was essential for
stimulation of cholesterol efflux [47].
We next compared the proportion of apoA-I surface binding to
membrane domains that are enriched in caveolae (Fig. 3). To
determine apoA-I binding to raft and non-raft domains, we
fragmented cells to which 125I-labelled apoA-I was first bound at
4uC. 125I-labelled apoA-I that detached from membranes
(13.765.6% of apoA-I bound to either cell type) appeared as a
pellet at the bottom of the gradient [47] and was not included in
the data in Figure 3. Similar to Figure 2, we found a 2.5-fold
reduction of apoA-I binding to Cav12/2 MEFs compared to WT
MEFs. The reduction in binding is particularly obvious in non-raft
domains: the vast proportion of the additional binding sites
associated with expression of Cav1 was not raft-associated because
they partitioned into non-raft domains in the isolation procedure.
However, when apoA-I in NDR is expressed as a proportion of
bound apoA-I, we found no difference between WT MEFs
(7.361.3% of bound apoA-I in NDR) and Cav12/2 MEFs
(8.260.6% of bound apoA-I in NDR) and consequently no
difference in proportional apoA-I binding to non-rafts between
WT (85.363.2%) and Cav12/2 MEFs (86.360.4%). Hence the
expression of Cav1 had no significant effects on cholesterol levels
in NDR (Fig. 1E), nor on the relative distribution of apoA-I
between raft and non-raft membrane domains. In summary, we
made the surprising discovery that Cav1 expression in MEF
induce apoA-I binding sites that have the biochemical character-
istics of non-raft domains.
ApoA-I processing
Both caveolae and non-caveolar rafts can act as entry portals for
bacterial toxins, viruses and plasma proteins, as reviewed in
reference [1]. Cav12/2 fibroblasts have impaired uptake of
albumin (but not transferrin receptor [2]) and reduced internal-
ization of raft marker GM1 whose uptake in wildtype cells is
initiated when integrin are dis-engaged and cells are detached
from the substratum [58,59]. It has been suggested that
internalization of apoA-I is important for stimulation of cholesterol
export [40,60,61] but it is not known if apoA-I endocytosis
involves caveolae and whether caveolar uptake is required for
cholesterol export.
We investigated the binding, uptake and degradation of 125I-
labeled apoA-I by WT and Cav12/2 cells at 37uC (Fig. 4). As
with apoA-I binding at 4uC (Fig. 2), apoA-I binding at 37uC was
Figure 2. ApoA-I binding to WT and Cav12/2 MEFs at 46C. A.–B. 125Iodine-labeled apoA-I (0–50 mg/mL) was bound to WT (solid diamonds)
and Cav12/2 MEFs (open squares) at 4uC on ice. Prior to exposure to apoA-I, cells in B, but not A, were treatment with the LXR agonist T0901317.
Specific binding was determined by competition with 10-fold excess of unlabeled apoA-I. Specifically bound apoA-I was normalized to cell protein.
The data (symbols) are a representative of independent experiments each performed in triplicate cell cultures. Solid lines represent best fits as
described in Methods. C. The number of maximum binding sites, Bmax and the binding affinity parameter KD (2 LXR agonist shown in filled bars,
+ LXR agonist hollow bars) obtained from the fit are shown as average 6 range of two independent experiments each performed in triplicates. No
difference (P.0.05) was found 6 LXR agonist treatment.
doi:10.1371/journal.pone.0023353.g002
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markedly reduced in Cav12/2 MEFs compared to WT MEFs at
all incubation times (Fig. 4A, left panels). ApoA-I internalization
(Fig. 4B, left panel) was also significantly lower in Cav12/2
MEFs. This is in agreement with a previous report in which
apoA-I surface binding strongly correlates with apoA-I internal-
ized over a range of different cell conditions [42]. Degradation of
apoA-I (Fig. 4C) could only reliably detected from 30 min
onwards, when WT cells degraded apoA-I 5-fold faster that
Cav12/2 MEFs. This is also in agreement with previous findings
that suggest that internalized apoA-I after a 2 h incubation at
37uC is largely targeted for lysosomal degradation [44]. Hassan
et al. did not find any significant degradation of apoA-I in
ABCA1-overexpressing BHK cells [42] while apoA-I endocytosed
by macrophages is largely degraded [43] suggesting a cell-type
specific effect.
ApoA-I and ABCA1 colocalize in endosomal compartments
[61,62,63] and recent conflicting reports have implicated [41,42] or
refuted [43,44] the role of ABCA1 in apoA-I internalization,
degradation and re-secretion. Here we assessed the effect of ABCA1
upregulation on apoA-I processing in WT and Cav12/2 MEFs.
Interestingly, when ABCA1 expression was upregulated by
T0901317 (Fig. 4 right panels), apoA-I binding at 37uC was initially
the same as non-induced cells but increased up to 1.7-fold and 2.7-
fold on WT and Cav12/2MEFs, respectively, after 2 h incubation
with apoA-I. It has been previously suggested that apoA-I
stimulated membrane reorganization at the cell surface at 37uC
[54,64] in an ABCA1-dependent manner [65] to create ‘mush-
room-like’ membrane protrusion to which apoA-I binding prefer-
entially. Hence the increase in apoA-I binding sites in Cav12/2
MEFs may be apoA-1-induced, ABCA1-dependent membrane
protrusions.
Although consistently lower than in non-treated cells (left panel),
treatment with the LXR agonist did not significantly alter apoA-I
internalization in either cell type (Fig. 4B, right panel) so that WT
cells displayed higher apoA-I internalization compared to Cav12/2
MEFs. ApoA-I degradation after 1 h at 37uC was lower upon LXR
agonist treatment of WT MEFs but higher upon treatment of
Cav12/2MEF (Fig. 4C, right panel). Hence LXR agonist treatment
may result in retaining apoA-I at the cell surface inWTMEFs with a
concomitant decrease in internalization and degradation while in
Cav12/2MEFs, LXR agonist treatment in conjunction with apoA-I
incubation increases apoA-I binding and degradation.
Taken together the data suggest that expression of caveolin
stimulates apoA-I surface binding, uptake and degradation in
fibroblasts. In contrast, ABCA1 expression alone (e.g. short apoA-I
incubation or low temperatures) does not increase apoA-I binding
sites in WT or Cav12/2 MEFs. Since apoA-I degradation is
severely reduced in Cav12/2 MEFs, our data suggest that
caveolae-mediated uptake of apoA-I leads to degradation.
Cholesterol efflux from WT and Cav12/2 MEFs
Previous reports have suggested that apoA-I or HDL uptake
and recycling back to the plasma membrane facilitates cholesterol
export [40,61,66]. This debate has become more intense with the
conflicting data on the role of ABCA1 in this retrograde
cholesterol transport route [41,42,43,44]. Given the different
internalization rates of apoA-I in WT and Cav12/2 MEFs, we
analyzed cholesterol efflux to apoA-I and HDL from these cells
(Fig. 5). Consistent with previous findings [10], we observed that
loss of Cav1 expression had no effect on cholesterol efflux
stimulated by HDL (data not shown). Efflux to HDL depends on
SR-BI and ABCG1 those levels are similar in both cell types
(Fig. 1B and data not shown). We also found no difference in total
cholesterol levels or unesterified cholesterol between these two cell
types, although cholesterol esters were elevated in Cav1-deficient
cells (Table 1). However, we did detect a consistent and
reproducible 1.7 (60.5)-fold increase in cholesterol efflux to
apoA-I from Cav12/2 MEFs compared to WT MEFs over a 24-
hour efflux period (Fig. 5A). In contrast, phospholipid efflux to
apoA-I was comparable between the two cell types (Fig. 5B,
P.0.05). It should be noted that much lower apoA-I concentra-
tions are required to saturate cholesterol efflux (,10 mg/mL) than
apoA-I surface binding (,50 mg/mL, Fig. 2A) suggesting that only
a small proportion of surface-bound apoA-I functions in
cholesterol efflux. In summary, WT MEFs have more apoA-I
binding sites and higher rates of apoA-I internalization but lower
cholesterol efflux than Cav12/2 MEFs. Hence the data show no
correlation between internalization and cholesterol efflux and
indicates that an efficient efflux pathway from caveolin-deficient
cells exists, which is unlikely to require apoA-I uptake.
We next examined cholesterol efflux from cells treated with
the LXR agonist. This treatment had no effect on cholesterol
efflux to HDL (data not shown) but increased apoA-I-dependent
efflux 2.0-fold and 3.3-fold from WT and Cav12/2 MEFs,
respectively (Fig. 5C). Thus increasing ABCA1 expression
increased cholesterol efflux from both cell types. Curiously,
efflux from Cav12/2 MEFs is higher than from WT MEFs
despite the lower ABCA1 surface expression in this cell type
(Fig. 1D). It has previously been suggested that the rate-limiting
step in cholesterol efflux to apoA-I is the intracellular cholesterol
transport [49]. In MEFs, LXR agonist treatment disproportion-
ally increased intracellular ABCA1 (compare Fig. 1B to Fig. 1D)
and thus is possible that T0901317 treatment enhances efflux
from MEF by stimulated intracellular cholesterol trafficking, as
previously suggested [61]. Taken together, our data suggest that
a surface pool of apoA-I outside caveolae mediates ABCA1-
dependent efflux, for which Cav1-mediated apoA-I internaliza-
tion may not be required.
Discussion
Caveolae are generally regarded as a subclass of lipid rafts
involved in signal transduction [1], membrane trafficking [67] as
well as mechanosensing [68] and mitosis [69]. Here we examined
the effect of Cav1 expression on apoA-I surface binding,
internalization and export using WT and Cav12/2 MEFs. While
Figure 3. ApoA-I binding to NDR and non-raft membranes in
WT and Cav12/2 MEFs. ApoA-I binding to light (fractions 2–5, filled
bars) and heavy (fractions 8–12, hollow bars) membranes was
quantified by scintillation counting. ApoA-I (50 mg/mL) was bound at
4uC on ice and MEFs were fractionated into NDR and non-raft
membranes as described for Fig. 1E. Data are average 6 standard
deviation of five experiments.
doi:10.1371/journal.pone.0023353.g003
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fibroblasts do not normally accumulate or export large quantities
of cholesterol in vivo, we nevertheless chose this model cell lines to
assess this question because the expression of transports such as
ABCA1, ABCG1 and SR-BI, the level of membrane-associated
cholesterol and abundance of lipid rafts are all similar in both cell
types under basal conditions. The underlying mechanisms of
apoA-I processing and cholesterol efflux should be cell-type
independent but are controlled by the expression levels of lipid
transporters. Similarly, while quantitative differences exist
between that rates of cholesterol efflux between mouse and
human cells, the processes are qualitatively similar, with
cholesterol efflux to apoA-I being primarily dependent on
ABCA1 in both species. We can draw three main conclusions
from this work. Firstly, Cav1 but not ABCA1 expression per se
increases the number of apoA-I binding sites on the cell surface of
MEFs. Secondly, Cav1-mediated apoA-I binding enhances apoA-
I internalization and degradation. Thirdly, Cav1-mediated apoA-
I binding and uptake does not correlate with cholesterol export.
In summary, our data suggest that non-caveolar domains provide
the surface pool of apoA-I that functions in cholesterol efflux in
fibroblasts while caveolae act as entry portal targeting apoA-I for
degradation (Fig. 6). These two apoA-I processing pathways are
likely to function independently.
The contradicting reports of the role of Cav1 in cholesterol
export could be due to the different cell types used in these studies
[10,28,29,31,32,33,34,37,38] that exhibit various expression levels
of lipid transporters. Further, knock-down of Cav1 expression,
used in [31,32,33], may not completely abolish caveolae from the
cell surface, while caveolin over-expression, employed in
[28,29,34,38] may not enhance caveolae formation since expres-
Figure 4. Specific apoA-I binding (A), internalization (B) and degradation (C) in WT and Cav12/2MEFs at 376C without (left column)
and with (right column) prior LXR agonist T0901317 treatment.WT (filled bars) and Cav12/2 (hollow bars) MEFs were incubated with 25 mg/
mL 125I-apoA-I 610-fold unlabeled excess at 37uC for 15 min to 2 h. Media were collected and cells were incubated with 0.5 mg/mL trypsin for
30 min at 4uC on ice. Supernatants were collected and counted to determine surface-bound apoA-I. Cells were lysed and 125I-apoA-I counted to
determined internalized apoA-I without surface-bound and degraded apoA-I. Degraded apoA-I in the medium was determined as TCA-soluble 125I-
apoA-I. In A–C, specific apoA-I levels are shown with non-specific apoA-I subtracted. Total cell-associated apoA-I is the sum of surface bound (A) and
internalized (B) apoA-I. ApoA-I levels are expressed relative to cell protein. Data are average 6 standard deviation of one of two representative
experiments performed in triplicate cell cultures. Asterisks indicate a significant difference (P.0.05) 6 LXR agonist treatment.
doi:10.1371/journal.pone.0023353.g004
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sion levels of cavins can become limiting factor in caveolae
generation [3]. In addition, manipulating Cav1 expression level
can affect cholesterol levels and the intracellular cholesterol
balance, expression and distribution of lipid transporters such as
ABCA1, which may alter cholesterol distribution in the plasma
membrane [19,20,21,22,55]. All of these effects would result in
modulated cholesterol export. In addition to function in mechan-
osensing [68] and mitosis [69], a number of reports have suggested
that caveolae act as entry portals for bacterial toxins and viruses
[1,5]. We found that expression of caveolin correlated with the
increased uptake of apoA-I. Furthermore, Cav1-dependent apoA-I
uptake enhances apoA-I degradation. The reduced uptake of
apoA-I, but enhanced apoA-I-dependent cholesterol efflux in
Cav12/2 MEFs suggests that this apoA-I uptake pathway is not
required for, and possibly competes with cholesterol efflux. At
present, we cannot exclude the possibility that a small, caveolin-
independent proportion of apoA-I uptake is indeed required for
cholesterol efflux from MEFs.
A number of groups investigated whether ABCA1 facilitates
apoA-I internalization and whether an ABCA1-dependent retro-
endocytosis pathway is a major efflux mechanism. Retro-
endocytosis requires the internalization by endocytic carriers and
re-secretion of intact, lipidated apoA-I [40,70] as previously
demonstrated by the transcytosis of apoA-I across endothelial cells
[71]. ABCA1 itself is internalized during cholesterol efflux [22,72]
but pharmacological retention of ABCA1 on the cell surface
correlated with both decreased [41,73] and increased [73]
cholesterol efflux. Hassan et al. showed that apoA-I induced
ABCA1 endocytosis to facilitate apoA-I re-secretion [42] in a
BHK cell system that over-expressed ABCA1 [55]. In contrast,
Denis et al. and Faulkner et al. found that the majority of
internalized apoA-I was targeted for degradation in macrophages
and fibroblasts with the minor amount of re-secreted apoA-I being
insufficient to qualify as a major cholesterol export pathway
[43,44]. Furthermore, inhibition of apoA-I internalization did not
decrease cholesterol efflux [44] and CHO cells transfected with
ABCA1 displayed enhanced efflux but decreased apoA-I uptake
[43]. It should be noted that caveolin expression was not
independently assessed in these studies and that the cell types
used have vastly different levels of caveolae. Hence the basal
condition i.e. no or little ABCA1 expression may not be
comparable in these reports. The latter reports in fibroblasts and
macrophages are consistent with our data that suggest that Cav1-
dependent but ABCA1-independent endocytosis mediates apoA-I
degradation and is not required for cholesterol efflux from
embryonic fibroblasts.
We found a striking reduction in the number of apoA-I binding
sites on the cell surface on Cav12/2 compared to WT MEFs.
Surprising the additional apoA-I binding sites in WT cells were
not found in the raft fraction where Cav1 elutes but in the non-raft
fraction. It should be kept in mind that the fractionation method is
not a definite proof of raft association. However the result does
suggest that apoA-I association with caveolae is rather weak or
that apoA-I binds to the caveolae/plasma membrane interface (see
below). Irrespectively of the precise location of the Cav1-mediated
apoA-I binding sites on the cell surface, it is unlikely that these
binding sites are required for cholesterol efflux. In this context it
should be pointed out that relatively low concentrations of apoA-I
(10 mg/mL) are sufficient to achieve maximum cholesterol efflux
while apoA-I binding to the cell surfaces saturates at much higher
concentrations (.50 mg/mL). Hence, few specific apoA-I binding
sites may efficiently facilitate cholesterol efflux. Since the apoA-I
binding affinity to the surface of Cav12/2 and WT MEFs is
similar, our data proposes that such specific, high-affinity binding
sites are independent of Cav1 expression.
Phillips and co-workers [64] proposed an efflux model with two
distinct types of apoA-I-membrane interactions: (i) apoA-I binding
to ABCA1 occurs at low capacity (,10% of total apoA-I binding)
but is critical for the activation of the lipid translocase and (ii)
apoA-I binding directly to lipids at a high capacity, which mediates
lipid removal from the plasma membrane. For the latter,
perturbed phospholipid bilayers [74] or membranes with high
curvatures are preferred since the extra space between the polar
head groups of the phospholipids allows the insertion of the
Figure 5. ApoA-I-induced cholesterol efflux from WT and
Cav12/2 MEFs. A. Kinetics of cholesterol efflux to 10 mg/mL apoA-I
from WT (closed diamonds) and Cav12/2 MEFs (open squares) over
24 h. Data is one representative experiment performed in triplicate cell
cultures. B. Phospholipid efflux to apoA-I from WT and Cav12/2 MEFs
after 24 h. C. Cholesterol efflux (6 h) to 10 mg/mL apoA-I from WT
(0.560.1 nmol/mg cell protein) and Cav12/2 MEFs (1.060.1 nmol/mg)
in the absence (left panel) and following treatment with the LXR agonist
T0901317 (right panel; WT MEF: 0.960.2 nmol/mg; Cav12/2 MEFs:
3.760.6 nmol/mg) was determined as described in Methods. The data is
one representative experiment of six, each performed in triplicate cell
cultures. Asterisks indicate a significant difference (P.0.05) 6 LXR
agonist treatment.
doi:10.1371/journal.pone.0023353.g005
Table 1. Cholesterol (Chol) content of WT and Cav12/2 MEFs.
Total Chol.
nmol/mg
Free Chol.
nmol/mg
Esterified Chol.
nmol/mg
WT MEFs 58.664.9 56.365.8 2.361.9 (4.0%)*
Cav12/2 MEFs 65.869.7 58.668.3 7.262.8 (10.8%)
Unesterified (free) and esterified cholesterol was analyzed by HPLC and
normalized to cell protein. Values are mean (6 S.D.) of six separate cultures.
Values in brackets give the percentage of esterified cholesterol of total
cholesterol. Asterisk indicates a significant difference of P,0.05.
doi:10.1371/journal.pone.0023353.t001
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amphipathic a-helices of apoA-I. The insertion the C-terminal a-
helix of apoA-I into the cell membranes and protein-free lipid
bilayers is critical for the extraction of lipids, as demonstrated
previously with apoA-I truncation mutants [74]. The seemingly
contradicting finding of Cav1-induced apoA-I binding sites that
have the biochemical characteristics of non-raft domains can be
reconciled if apoA-I binds to the neck of caveolae. The high
curvature at the caveolae neck makes the membrane packing
unfavorable for raft lipids and thus may constitute domains that
preferentially partition into non-raft fractions.
Based on the mechanisms described above [64], we propose a
model (in which apoA-I binds specifically to domain interfaces, such
as the interface of raft and non-raft domains or the necks of caveolae
(Fig. 6). This is consistent with our observation that Cav1 expression
increases the number of apoA-I binding sites but not the proportion
of apoA-I associated with raft domains. Further, increased
expression of ABCA1 would have little effect on the overall number
of initial apoA-I binding sites in both WT and Cav12/2 cells, as
previously reported for macrophages [54], since ABCA-1 is unlikely
to increase the domain interface. ApoA-I interaction with domain
interfaces would explain why cholesterol export is dependent on an
initial interaction of apoA-I with lipid raft domains in the plasma
membrane [47] although ABCA1 and ABCA1-dependent choles-
terol efflux is not raft-associated [18]. Vedhachalam et al. further
suggest that ABCA1 translocase activity forces the membrane to
bend inducing filopodia formation and thus additional apoA-I
binding sites [64]. This hypothesis could explain our observation of
increased apoA-I binding sites on Cav12/2 cells with high ABCA1
expression upon prolonged incubation at 37uC. This was not
observed in WT cells where these additional sites may be obscured
by caveolae-mediated binding sites. As previously suggested [64], in
our model ABCA1 mainly functions as a lipid translocase to aid the
lipid extraction process of apoA-I already bound to the plasma
membrane. Since cholesterol efflux saturates at relatively low apoA-
I concentration, Cav1-independent, high affinity apoA-I binding
sites, rather than ABCA1 expression levels at the surface, may be
rate limiting for cholesterol efflux to apoA-I.
In conclusion, our study illustrates the usefulness of Cav1-deficient
fibroblasts as an experimental model that allows the delineation of
Cav1- and ABCA1-controlled apoA-I pathways. While caveolae
may constitute binding sites and entry portals for apoA-I, it is
unlikely that these high capacity binding sites and Cav1-mediated
internalization of apoA-I is required for efflux. Instead, our data
suggest that membrane domains other than caveolae compensate for
the loss of apoA-I binding in Cav12/2 cells and imply that lipidation
of apoA-I takes place at the cell surface in a process that is ABCA1-
dependent. It has been demonstrated that ABCA1 resides in non-raft
domains [22,47] but the precious location of apoA-I lipidation is yet
to be resolved. One possibility is that raft domains or domain
interfaces in the vicinity of ABCA1 provide the reservoir of substrate
for ABCA1. Identification of the preferred substrate of ABCA1 may
elucidate the interdependencies of apoA-I, lipid domains and
ABCA1 that are necessary to facilitate efflux.
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Figure 6. Model of the role of membrane domains in apoA-I-mediated cholesterol efflux. Predominantly saturated phospholipids (color
red and yellow) and cholesterol (yellow squares) form domains (lipid rafts, caveolae) that are distinct from more fluid, non-raft domains (grey lipids).
A. High-capacity apoA-I binding sites preferentially form at the raft/non-raft border where disordered lipid packing creates space for the insertion of
apoA-I’s amphipathic a-helices between the phospholipids polar head groups. B. Caveolae at the plasma membrane form a ring of high membrane
curvature at its neck to which apoA-I may bind with high capacity. ApoA-I bound at the caveolae neck is targeted for internalization and degradation
(dashed arrow) and is not required for lipid efflux (grey arrow) C. ABCA1 expression does not mediate high capacity apoA-I binding sites. Stimulation
of ABCA1 translocase activity by apoA-I facilitates efflux (solid black arrow) and may create additional apoA-I binding sites.
doi:10.1371/journal.pone.0023353.g006
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